We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi (SNY), GSK Receive EU Approval for COVID-19 Vaccine
Read MoreHide Full Article
Sanofi (SNY - Free Report) announced that the European Commission (“EC”), on Nov 10, approved VidPrevtyn Beta, its next-generation protein-based adjuvanted vaccine. The vaccine can be given as a booster for preventing COVID-19 in adults aged 18 years and older. The vaccine has been developed in partnership with GSK (GSK - Free Report) .
Following the EC approval, VidPrevtyn Beta can be used as a booster dose in adults who have already been vaccinated with an mRNA-based vaccine developed by Pfizer (PFE - Free Report) /BioNTech (BNTX - Free Report) and Moderna or an adenoviral vaccine developed by AstraZeneca. Per Sanofi/GSK, the vaccine doses are ready to be shipped to member states of the EU.
The EC decision follows the positive opinion issued by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) which also recommended approving the vaccine. The EC decision came a couple of hours after the CHMP recommended the vaccine. The EC and CHMP decisions are based on data from two immunobridging studies, which compared the immune response generated by the Sanofi/GSK partnered vaccine against authorized mRNA-based or adenoviral vaccines.
Based on its analysis of data, the CHMP and EC concluded that a booster dose of VidPrevtyn Beta is expected to be at least as effective as Pfizer/BioNTech’s Comirnaty at restoring protection against COVID-19.
Shares of Sanofi have lost 11.6% this year against the industry’s 3.7% rise.
Image Source: Zacks Investment Research
VidPrevtyn Beta has been developed by Sanofi using its recombinant-protein technology platform and modeled on the Beta variant. The vaccine also utilizes GSK’s pandemic adjuvant platform.
We note that the approval comes when the COVID-19 infections are waning. In fact, the COVID-19 vaccine market is dominated by Pfizer/BioNTech and Moderna, which already have monovalent and bivalent vaccines authorized for use in the European Union. Pfizer/BioNTech and Moderna have already immunized millions of individuals across Europe and its BA.1 and BA.4/5 bivalent vaccines, which the EC has recently authorized, are in full force for supply to EU member states.
Image: Bigstock
Sanofi (SNY), GSK Receive EU Approval for COVID-19 Vaccine
Sanofi (SNY - Free Report) announced that the European Commission (“EC”), on Nov 10, approved VidPrevtyn Beta, its next-generation protein-based adjuvanted vaccine. The vaccine can be given as a booster for preventing COVID-19 in adults aged 18 years and older. The vaccine has been developed in partnership with GSK (GSK - Free Report) .
Following the EC approval, VidPrevtyn Beta can be used as a booster dose in adults who have already been vaccinated with an mRNA-based vaccine developed by Pfizer (PFE - Free Report) /BioNTech (BNTX - Free Report) and Moderna or an adenoviral vaccine developed by AstraZeneca. Per Sanofi/GSK, the vaccine doses are ready to be shipped to member states of the EU.
The EC decision follows the positive opinion issued by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) which also recommended approving the vaccine. The EC decision came a couple of hours after the CHMP recommended the vaccine. The EC and CHMP decisions are based on data from two immunobridging studies, which compared the immune response generated by the Sanofi/GSK partnered vaccine against authorized mRNA-based or adenoviral vaccines.
Based on its analysis of data, the CHMP and EC concluded that a booster dose of VidPrevtyn Beta is expected to be at least as effective as Pfizer/BioNTech’s Comirnaty at restoring protection against COVID-19.
Shares of Sanofi have lost 11.6% this year against the industry’s 3.7% rise.
Image Source: Zacks Investment Research
VidPrevtyn Beta has been developed by Sanofi using its recombinant-protein technology platform and modeled on the Beta variant. The vaccine also utilizes GSK’s pandemic adjuvant platform.
We note that the approval comes when the COVID-19 infections are waning. In fact, the COVID-19 vaccine market is dominated by Pfizer/BioNTech and Moderna, which already have monovalent and bivalent vaccines authorized for use in the European Union. Pfizer/BioNTech and Moderna have already immunized millions of individuals across Europe and its BA.1 and BA.4/5 bivalent vaccines, which the EC has recently authorized, are in full force for supply to EU member states.
Sanofi Price
Sanofi price | Sanofi Quote
Zacks Rank
Sanofi currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.